Sponsor of the Day:
Jerkmate
https://www.biopharmadive.com/news/survodutide-obesity-drug-results-boehringer-ingelheim-zealand/818664/
Boehringer dual-acting obesity shot hits mark in Phase 3 trial | BioPharma Dive
Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.
phase 3 trialshot hitsbiopharma diveboehringerdual
https://www.biopharmadive.com/news/astellas-again-hits-pause-on-gene-therapy-trial/605928/
Astellas again hits pause on gene therapy trial | BioPharma Dive
The company is holding off dosing more patients with AT132, a potential treatment for a deadly neuromuscular disease, after one recently experienced a serious...
gene therapy trialhits pausebiopharma diveastellas
https://www.biopharmadive.com/news/revolution-pancreatic-cancer-ras-drug-results/817300/
Revolution pancreatic cancer drug nearly doubles survival in key trial | BioPharma Dive
The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a tough-to-treat tumor.
trial biopharma divepancreatic cancernearly doublesrevolutiondrug